Search hospitals > California > Santa Monica
Providence Saint John's Health Center
Claim this profileSanta Monica, California 90404
Conducts research for Melanoma
Conducts research for Bladder Cancer
Conducts research for Breast Cancer
Conducts research for Cancer
Conducts research for Solid Tumors
38 reported clinical trials
8 medical researchers
Summary
Providence Saint John's Health Center is a medical facility located in Santa Monica, California. This center is recognized for care of Melanoma, Bladder Cancer, Breast Cancer, Cancer, Solid Tumors and other specialties. Providence Saint John's Health Center is involved with conducting 38 clinical trials across 102 conditions. There are 8 research doctors associated with this hospital, such as Santosh Kesari, MD, Naveed Wagle, MD, Parvin Peddi, MD, and Orrin Troum, MD.Area of expertise
1Melanoma
Stage IV
Stage III
BRAF positive
2Bladder Cancer
Stage IV
Stage III
Top PIs
Santosh Kesari, MDProvidence Saint John's Health Center4 years of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
12 reported clinical trials
16 drugs studied
Naveed Wagle, MDProvidence Saint John's Health Center4 years of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
7 reported clinical trials
8 drugs studied
Parvin Peddi, MDSaint John's Cancer Institute3 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
7 reported clinical trials
19 drugs studied
Orrin Troum, MDOrrin M Troum and Medical Associates2 years of reported clinical research
Studies Rheumatoid Arthritis
Studies Gout
7 reported clinical trials
7 drugs studied
Clinical Trials running at Providence Saint John's Health Center
Cancer
Solid Tumors
Skin Cancer
Ovarian Cancer
Breast Cancer
Liver Cancer
Urothelial Carcinoma
Hematologic Malignancies
Prostate Cancer
Renal Cell Carcinoma
MDNA11 + Pembrolizumab
for Cancer
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Recruiting1 award Phase 1 & 2
Emavusertib +/- Ibrutinib
for CNS Lymphoma
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated in combination with ibrutinib at 560 milligrams (mg) once daily (QD) or 420 mg QD as indicated by disease (Part A2 complete). Part B will comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R/R primary central nervous system lymphoma (PCNSL) who have directly progressed on a bruton tyrosine kinase inhibitor (BTKi). In this part of the study, emavusertib will be dosed at 100 mg or 200 mg twice daily (BID) in combination with ibrutinib in 28-day treatment cycles. Part C will comprise 3 treatment arms in the second-line setting to assess the efficacy and safety of emavusertib monotherapy, ibrutinib monotherapy, and emavusertib in combination with ibrutinib in participants with R/R PCNSL who are naïve to BTKi treatment. In this part of the study, eligible second-line participants with R/R PCNSL who are naïve to BTKi treatment will be randomized 1:1:1 to 1 of 3 treatment arms: (1) emavusertib 200 mg BID, (2) ibrutinib 560 mg QD, or (3) emavusertib 200 mg BID in combination with ibrutinib 560 mg QD.
Recruiting1 award Phase 1 & 21 criteria
AdAPT-001
for Cancer
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Recruiting1 award Phase 217 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Providence Saint John's Health Center?
Providence Saint John's Health Center is a medical facility located in Santa Monica, California. This center is recognized for care of Melanoma, Bladder Cancer, Breast Cancer, Cancer, Solid Tumors and other specialties. Providence Saint John's Health Center is involved with conducting 38 clinical trials across 102 conditions. There are 8 research doctors associated with this hospital, such as Santosh Kesari, MD, Naveed Wagle, MD, Parvin Peddi, MD, and Orrin Troum, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.